

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50111/043002
		Serial No.	09/215,163
		Applicant	Stinson et al.
		Filing Date	December 18, 1998
		Group	1645
		IDS Filed	August 13, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	WO 1998/11229	Mar. 19, 1998	WIPO	
	WO 2007/098201	Aug. 30, 2007	WIPO	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Boyd et al., "Serological responses to the B subunit shiga-like toxin 1 and its peptide fragments indicate that the B subunit is a vaccine candidate to counter the action of the toxin," <i>Infection and Immunity</i> 59: 750-757 (1991).
	Cox et al., "Adjuvants – a classification and review of their modes of action," <i>Vaccine</i> 15: 248-256 (1997).
	Morrison, "With FDA talks stalled, Thallion looks abroad," <i>BioWorld Today</i> 30 Oct. 2007: 18: 1-7.
	"Clinical roundup", <i>Bioworld Today</i> 28 Mar. 2008: 19: 2.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	